

**NC Medicaid and NC Health Choice  
Pharmacy Prior Approval Request for**

**Antinarcoplepsy: Xyrem®**

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescribing Provider NPI #: \_\_\_\_\_  
7. Requester Contact Information - Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 30 Days: \_\_\_\_\_  
11. Length of Therapy (in days): Initial Authorization:  up to 30 Days  60 Days  90 Days  
Reauthorization:  up to 30 Days  60 Days  90 Days  
 120 Days  180 Days

**Clinical Information**

1. Is the beneficiary 7 years of age or older?  Yes  No
2. Does the beneficiary have any current use of alcohol or sedative hypnotics?  Yes  No
3. Does the beneficiary have succinic semialdehyde dehydrogenase deficiency?  Yes  No
4. Has the beneficiary been evaluated for history of drug abuse?  Yes  No
5. Will the prescriber monitor the beneficiary for signs of misuse or abuse of sodium oxybate (a.k.a. gamma-hydroxybutyrate [GHB]) including, but not limited to, the following: Use of increasingly large doses, increased frequency of use, drug-seeking behavior, feigned cataplexy, etc.?  Yes  No
6. Does the beneficiary have a diagnosis of cataplexy associated with narcolepsy?  Yes  No
7. Does the beneficiary have a diagnosis of excessive daytime sleepiness due to narcolepsy with daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for  $\geq$  3 months?  Yes  No
8. Does the beneficiary have hypersomnolence secondary to another sleep disorder, neurologic disorder, medical condition, or by medicine or substance use has been ruled out?  Yes  No

**For continuation of therapy, please answer questions 1-10**

9. For a diagnosis of excessive daytime sleepiness, has the beneficiary responded to therapy with a reduction in excessive daytime sleepiness from pre-treatment baseline measured by a validated scale (e.g., Epworth Sleepiness Scale, Stanford Sleepiness Scale, Karolinska Sleepiness Scale, Cleveland Adolescent Sleepiness Questionnaire, or a Visual Analog Scale)?  Yes  No
10. For a diagnosis of cataplexy, has the beneficiary had a reduced frequency of cataplexy attacks from pretreatment baseline?  
 Yes  No



**NC Medicaid and NC Health Choice  
Pharmacy Prior Approval Request for**

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to **1-800-678-3189**

Pharmacy PA Call Center: **1-866-799-5318**